Wise, T
Marwood, L
Perkins, A M
Herane-Vives, A
Joules, R
Lythgoe, D J
Luh, W-M
Williams, S C R
Young, A H
Cleare, A J
Arnone, D
Article History
Received: 11 June 2016
Revised: 14 December 2016
Accepted: 9 January 2017
First Online: 25 April 2017
Competing interests
: AJC has in the last 3 years received honoraria for speaking from AstraZeneca, honoraria for consulting from Allergan and Livanova and research grant support from Lundbeck. DJL has consulted for Ixico PLC. AHY has given paid lectures and sits on advisory boards for all major pharmaceutical companies with drugs used in affective and related disorders; is the lead investigator for the Embolden Study (AZ), BCI Neuroplasticity study and Aripiprazole Mania Study and investigator-initiated studies from AstraZeneca, Eli Lilly, Lundbeck and Wyeth; and has received grant funding from the National Institute of Mental Health (USA); Canadian Institutes of Health Research (Canada); National Alliance for Research on Schizophrenia and Depression (USA); Stanley Medical Research Institute (USA); Medical Research Council (UK); Wellcome Trust (UK); Royal College of Physicians (Edinburgh); British Medical Association (UK); University of British Columbia-Vancouver General Hospital Foundation (Canada); Western Economic Diversification Canada (Canada); Canadian Cardiovascular Society Depression Research Fund (Canada); Michael Smith Foundation for Health Research (Canada); and National Institute for Health Research (UK). AMP is supported by Bionomics Limited. DA has received travel grants from Janssen-Cilag and Servier. SCRW has received grant funding from the Medical Research Council (UK); Wellcome Trust (UK); National Institute for Health Research (UK) and support for investigator-led studies from Takeda, Pfizer, Lundbeck, P1Vital, Roche and Eli Lilly. The remaining authors declare no conflict of interest.